Australia’s Healius on Tuesday said private equity firm Partners had offered to acquire the medical center operator for A$2.12 billion ($1.40 billion).
The Swiss private equity firm offered A$3.40 per share in cash, a 23.2% premium to Healius’ last closing price.
A filing earlier in the day showed Partners bought out China’s Jangh’s 15.9% majority stake in Healius.
Jangho had previously offered to buyout Healius for A$1.7 billion or A$3.25 per share, which was rejected by the Sydney-based company, saying it was “opportunistic” and fundamentally undervalued the company.
The company said it has not yet formed a view on Partners’ offer, adding that it was also subject to six weeks of due diligence.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
YouTube CEO Argues Google’s Innovation, Not Monopoly, Drove Ad Tech Success
Sep 16, 2024 by
CPI
Samsung, Xiaomi Among Smartphone Brands Allegedly Involved in eCommerce Collusion In India
Sep 16, 2024 by
CPI
Appeals Court Sides with Exxon, Chevron in Price-Fixing Lawsuit
Sep 16, 2024 by
CPI
Nvidia Faces Antitrust Lawsuit in Strategic Filing Move by Xockets Inc.
Sep 16, 2024 by
CPI
UK Competition Regulator to Reform Pay System Amid Bias Allegations
Sep 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández